Study shows improvement of rheumatoid arthritis during pregnancy

Disease activity in patients with rheumatoid arthritis (RA) is significantly reduced during pregnancy, according to new data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

In the study, RA improved significantly from the first trimester to the third trimester of the participants, pregnancy and this effect extended into the postpartum stage.

This is the first prospective study to confirm the relationship between RA and pregnancy, tracking 124 female RA patients throughout their pregnancy and at 6, 12 and 26 weeks postpartum. The RA improvement was seen in 40% of patients. Furthermore, 64% of patients remained relatively stable or improved postpartum. Only a third of patients (36%) experienced flares (periods of worsened symptoms), 5% severely.

Dr Yal de Man of Erasmus MC University Medical Center, Rotterdam, The Netherlands, who performed this research, said: Whilst previous literature has suggested an improvement of RA in pregnancy, this is the first prospective study to put a figure to this. The percentage of patients experiencing flares was much lower than previous studies, which we attribute to adequately-used DMARDs and biologicals to suppress disease activity postpartum. It is also interesting to note the existence of a complex interaction between female hormones during pregnancy and the epidemiology of RA, which may contribute to the development of new prevention and treatment approaches.

In the study, patients were assessed according to medication use, the Disease Activity Score DAS28 and the level of inflammation marker C-reactive protein (CRP). Disease activity was calculated with DAS28-CRP with 3 variables (DAS28-CRP-3). The change between the DAS28 at first and third trimester was used to categorise patients according to the EULAR response criteria into good, moderate and non-responders. The change between the DAS28 at 6 weeks and 12 or 26 weeks postpartum was used to determine if a severe or moderate flare was present.

The DAS28 decreased significantly during pregnancy from 3.7 (SD 1.1) in the first trimester to 3.4 (SD 1.1) in the third trimester (n=124, p=0.003). The mean DAS28 was 3.4 (SD 1.1) at six weeks postpartum. During pregnancy, 11% (49/124) were good responders, 40% were at least moderate responders (49/124) and 60% (75/124) were non-responders. The relapse of disease activity was present at twelve weeks postpartum with a mean DAS28 of 3.7 (SD 1.2) and was slightly lower at 26 weeks postpartum with a mean of 3.6 (SD 1.2). Postpartum, 5% (5/110) had a severe flare, 36% (40/110) had at least a moderate flare and 64% (70/110) remained relatively stable or improved.

During all trimesters, the percentages of DMARDs used were stable (sulfasalazine 32%, prednisone 35%, hydroxychloroquine 1% and gold i.m 1%), whilst DMARD use rose considerably postpartum (57% at the third trimester versus 82% post partum), mainly due to methotrexate (44%) and biologicals (8%).

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Here’s why getting a covid shot during pregnancy is important